Small Interfering RNA Market

1. Analysis of Small Interfering RNA Market Size by Research Nester Reveals the Market to Grow with a CAGR of ~18.5% During 2024-2036 and Attain ~USD 67 Billion by 2036 Research Nester assesses the growth and market size of global small interfering RNA market which is anticipated to be on account of the growing incidence of cancer and growing partnerships and collaborations between key market players. New York – September 26, 2023- Research Nester’s recent market research analysis on “Small Interfering RNA Market: Global Demand Analysis & Opportunity Outlook 2036” delivers a detailed competitors analysis and a detailed overview of the global small interfering RNA market in terms of market segmentation by type, end- user, indication and by region. Growing Cases of Neurodegenerative Disorders to Promote Global Market Share of Small Interfering RNA The global small interfering RNA market is estimated to grow majorly on account of the increasing prevalence of neurodegenerative diseases.The prevalence and incidence of these diseases rise rapidly with age, owing to exposure to environmental pollutants, bad lifestyle habits, vascular problems, and newly recognized risk factors such as hearing loss. Moreover, the use of siRNA-based drug delivery as a treatment option for neurodegenerative diseases is a viable avenue for the development of novel therapeutic techniques. Request Free Sample Copy of this Report @ https://www.researchnester.com/sample-request-5297

2. According to estimates, neurological illnesses are the primary cause of physical and cognitive disability worldwide, which impact over 12% of the global population. The global small interfering RNA market is estimated to grow majorly on account of the increasing trend of personalized medicines. Personalized medicine is a new medical practice that makes use of a person's genetic profile holds great promise for disease treatment and prevention, and represents an exciting opportunity to improve the future of individualized healthcare for all citizens. SiRNA therapy, commonly known as gene- silencers, is a type of personalized medicine that has emerged as a promising strategy for personalized cancer and other illness treatments. Some of the major growth factors and challenges that are associated with the growth of the global small interfering RNA market are: Growth Drivers: Surge in Drug Development Rising Elderly Population Globally Challenges: The exorbitant cost of small interfering RNA and the stringent regulations developed by the government of nations for the approval of small interfering RNA therapies worldwide are some of the major factors anticipated to hamper the global market size of small interfering RNA. Multiple clinical trials are conducted before bringing small interfering RNA therapies to the market. These trials are often expensive, which adds to the overall cost of the therapy. Besides this, the development of siRNA therapies involves extensive research & development that leads to higher costs.

3. Request for customization @ https://www.researchnester.com/customized-reports-5297 By type, the global small interfering RNA market is segmented into liposome based systemic therapy, and nanoparticle based systemic therapy. The nanoparticle-based systemic therapy segment is to garner a notable revenue by the end of 2036 by growing at a significant CAGR over the forecast period. The employment of nanoparticles for siRNA administration enhanced pharmacokinetics and is known to be more durable and stable Nano carriers than lipid Nanocarriers. For instance, various types of AuNPs have recently been extensively researched for siRNA delivery including gold nanoparticles (AuNPs) owing to their good biocompatibility, and ease of synthesis. Additionally, Patisiran, a small interfering RNA (siRNA) lipid nanoparticle-based medication, is currently the most advanced RNAi therapeutic approved by the FDA. By region, the Europe small interfering RNA market is to generate the highest revenue by the end of 2036. This growth is anticipated by growing product approvals in the region. For instance, Novartis received EU clearance for Leqvio, the first and only licensed small-interfering RNA (siRNA) LDL-C lowering medication in Europe. Furthermore, Leqvio produced an effective reduction in low-density lipoprotein cholesterol (LDL-C) of more than 50% in patients and is predicted to support long- term adherence with two doses per year. Besides this, the growing elderly population in European region may create a huge demand for small interfering RNA in the coming years. For instance, more than 20% of the EU population will be 65 or older in 2022. Moreover, one in every five Europeans is now 65 or older, and by 2050, it will be close to more than 25%. The elderly population is more likely to get affected by various age-related diseases including arthritis, and other

4. neurodegenerative diseases, which may drive the demand for siRNA in the region. This report also provides the existing competitive scenario of some of the key players of the global small interfering RNA market which includes company profiling of Thermo Scientific, Arbutus Biopharma, Sanofi Genzyme, Sylentis, Arrowhead Research, Genecon Biotechnologies, Silent Therapeutics, Horizon Discovery, OPKO Health, Agios Pharmaceuticals, Inc., Novartis, Takara Bio Inc., AstraZeneca PLC. Access our detailed report @ https://www.researchnester.com/reports/small-interfering- rna-market/5297 Research Nester is a leading service provider for strategic market research and consulting. We aim to provide unbiased, unparalleled market insights and industry analysis to help industries, conglomerates and executives to take wise decisions for their future marketing strategy, expansion and investment etc. We believe every business can expand to its new horizon, provided a right guidance at a right time is available through strategic minds. Our out of box thinking helps our clients to take wise decision in order to avoid future uncertainties. Contact for more Info: AJ Daniel Email: info@researchnester.com U.S. Phone: +1 646 586 9123 U.K. Phone: +44 203 608 5919